**Original Research Article**

DOI: 10.26479/2019.0504.06

ANTIBACTERIAL POTENTIAL OF SEA STAR *PROTOREASTER LINCKII* FROM MANDAPAM, SOUTHEAST COAST OF INDIAMohamed Hussain S^{1*}, Basith O¹, Chamundeeswari K², Chitra M¹

1. P.G. and Research Department of Zoology, Jamal Mohamed College (Autonomous), Tiruchirappalli-620020, Tamil Nadu, India.
2. National Centre for Sustainable Coastal Management, Anna University Campus, Chennai-600025, Tamil Nadu, India.

ABSTRACT: The present study was aimed to evaluate the antibacterial potential of the commonly available sea star *Protoreaster linckii*. The samples were collected from Mandapam, the Gulf of Mannar, southeast coast of India. Four different extracts like methanol, acetonitrile, dichloromethane and ethanol at varying concentrations ranging from 250 to 1000 µg/ml was used for the experiment to study the inhibitory effects on ten selected human urinary tract infectious pathogenic bacteria. A concentration dependent inhibitory effect was observed in all the extracts of star fish. The results of the study suggested that most of the extracts have strong inhibitory activity against different pathogens similar to the standard drugs. Methanolic extracts exhibited a maximum zone of inhibition (17.00±0.1mm) against gram positive *Staphylococcus saprophyticus* at the higher concentration. Minimum zone of inhibition (0.700±0.35 and 0.800±0.15 mm) were reported in gram positive *S. aureus* while using the median and higher concentrations of dichloromethane extracts.

KEYWORDS: Starfish, *Protoreaster linckii*, Antimicrobial activity, UTI

Corresponding Author: Dr. Mohamed Hussain S^{*Ph.D.}

Assistant Professor of Zoology, Jamal Mohamed College (Autonomous),
Tiruchirappalli-620020, Tamil Nadu, India. E-mail Address: mdhussainjmc@gmail.com

1.INTRODUCTION

Marine environment is the most productive ecosystem in the world that consists of abundant faunal and floral diversity [1]. Marine organisms contain numerous organic bioactive compounds including secondary metabolites [2]. These secondary metabolites were having applications in agrochemical, cosmeceutical, food, nutraceutical and pharmaceutical industries [3-5]. Secondary metabolites

having desirable antimicrobial properties were isolated from marine organisms [6-8] and they are also a rich realm comprising various antioxidant and anticancer natural compounds with low toxicity, high efficiency and none drug resistance [9]. Starfish commonly known as sea stars are marine benthic organisms belonging to the class Asteroidea that comes under the phylum Echinodermata. They have numerous tube feet, exhibits pentameral symmetry and have high regenerative ability. Starfish contains a number of biologically active compounds and molecule having pharmacological properties including anticoagulant, antifouling, antifungal, anti-inflammatory, antimicrobial, antiviral, cytotoxic, feeding deterrent, haemolytic, hemotoxic and wound healing activities [10-19]. Marine ecosystem of India consists of 7517 km coastline area spread across nine coastal states and two union territories that are covered by Arabian Sea, Bay of Bengal and Indian Ocean. Drug discoveries from marine non-chordates have an important research field since decades and Indian marine natural product research gained momentum only in the late seventies [20]. The data from available literatures revealed that taxonomical studies were conducted regarding some of the starfish in Indian coast, whereas studies on their pharmacological potential are very scare [21-22]. The sea star *Protoreaster linckii* also named as 'Red-knobbed Starfish' are widely distributed throughout the Indo-Pacific region. It has a gorgeous appearance with bright red or orange reticulate patterns on their dorsal sides and it feeds on sponges, sea anemones and soft corals [23]. The Gulf of Mannar, located along the southeastern part of Tamil Nadu, is a marine biosphere reserve extending from Rameswaram to Kanyakumari acts as a nursery ground for this starfish. Hence the sea star *P. linckii* was chosen as the experimental animal for the present study with an aim of identifying their antibacterial potential against the human urinary tract infectious pathogens.

2. MATERIALS AND METHODS

2.1. Sample collection and preparation of extracts

Live specimens of the starfish *Protoreaster linckii* were collected by scuba diving from an intertidal zone of Mandapam (Lat. 9°16'N; Long. 79°8'E), Tamil Nadu in the Gulf of Mannar along the southeast coast of India during January 2018. The samples were thoroughly washed with sea water and cleaned to remove debris and are immediately stored in ice box and transported to the Zoology laboratory of Jamal Mohamed College, Tiruchirappalli. The extraction process was carried out following the standard methodology [24]. Whole body of star fish samples were placed on different polar solvents such as methanol, acetonitrile, dichloromethane and ethanol separately in the ratio of 1:3 (w/v) for 72 hrs at normal room temperature. Then the extracts were filtered through Whatman No.1. filter paper and the solvents were concentrated by rotary evaporator (VC100A Lark Rotavapor®) at 30°C with reduced pressure to give predominantly an aqueous suspension and concentrated under reduced pressure to give a residue. The crude extracts were stored at 4°C and used for further analysis.

2.2. Antibacterial susceptibility assay

The clinical isolates of selected human urinary tract infectious pathogens were obtained from the Govt. Medical College Hospital, Tiruchirappalli. Antibacterial activity of the crude extracts of star fish were evaluated by well diffusion method [25]. The bacterial strains were enriched in nutrient broth overnight at 37°C. Then they were streaked over Mueller Hinton agar surface using sterile cotton swabs. Then wells were loaded with 50µl of different extracts at various concentrations (250, 500 and 1000 µg/ml). Streptomycin 400µl was used as positive control and negative control was prepared using distilled water. The plates were incubated at 37°C for 24 h. Antimicrobial activities were determined after 72h by measuring the diameter of inhibition zone around the disc and the results were expressed in millimeters.

2.3. Statistical analysis

All the assays were conducted in triplicates and the data were expressed as mean with standard error (SE). Bar diagrams was plotted using Origin software (Version 8.0).

3. RESULTS AND DISCUSSION

The four different extracts of *Protoreaster linckii* were subjected for their antibacterial activities and the results are summarized in Table 1-4. It is evident that the methanolic extract (Fig.1) has comparatively higher antibacterial potential against the selected gram positive and gram negative bacterial isolates followed by acetonitrile (Fig. 2), ethanol (Fig. 3) and dichloromethane (Fig. 4) extracts in a dose dependent manner. Higher concentration of methanolic extract exhibited a maximum zone of inhibition (17.00 ± 0.14) against Gram positive *Staphylococcus saprophyticus*, whereas medium to moderate inhibitions were reported for other three extracts such as acetonitrile (11.00 ± 0.36), dichloromethane (12.49 ± 0.65) and ethanol (14.00 ± 0.76) at the same concentration. Lower concentrations of extracts did not exhibited any zones of inhibition against gram positive *Staphylococcus aureus*, whereas minimum zone of inhibition was observed while using the median and higher concentration of all the four extracts with corresponding values of 1.000 ± 0.32 and 1.400 ± 0.20 (methanol), 1.200 ± 0.40 and 1.400 ± 0.47 (acetonitrile), 0.700 ± 0.35 and 0.800 ± 0.15 (dichloromethane), 0.900 ± 0.02 and 1.100 ± 0.31 (ethanol) respectively. The methanolic, ethanolic and acetonitrile extracts of this starfish at a concentration of 1000 µg/ml showed excellent inhibitory effects against the gram negative *Klebsiella pneumoniae* with higher zones of inhibition 8.500 ± 0.16 , 8.500 ± 0.42 and 7.500 ± 0.47 respectively and the values were higher than that of the standard drug (6.800 ± 0.36), however dichloromethane extract showed moderate zones of inhibition (4.500 ± 0.42) in the same species.

Table 1: Antibacterial activity of the methanolic extract of *Protoreaster linckii*

	Inhibition Zone (mm)				
	Concentrations of the extract µg/ml				
Pathogens	250	500	1000	Standard	Control
<i>Staphylococcus Saprophyticus</i>	15.23±0.42	16.30±0.10	17.00±0.14	20.00±0.12	----
<i>Escherichia coli</i>	10.15±0.28	12.13±0.23	12.59±0.32	18.21±0.31	----
<i>Klebsiella pneumonia</i>	6.900±0.47	7.300±0.16	8.500±0.16	6.800±0.36	----
<i>Pseudomonas aeruginosa</i>	6.500±0.36	7.100±0.27	7.000±0.36	18.52±0.16	----
<i>Enterobacter cloacae</i>	----	2.800±0.25	3.400±0.31	5.100±0.19	----
<i>Enterococcus faecalis</i>	2.100±0.20	2.600±0.42	2.800±0.17	5.300±0.23	----
<i>Staphylococcus aureus</i>	----	1.000±0.32	1.400±0.20	6.400±0.35	----
<i>Klebsiella oxytoca</i>	2.300±0.20	2.700±0.30	3.200±0.23	6.700±0.18	----
<i>Mycoplasma genitalium</i>	8.900±0.12	9.300±0.20	9.500±0.24	10.10±0.18	----
<i>Proteus mirabilis</i>	4.600±0.31	4.800±0.14	5.400±0.34	6.500±0.35	----

Table 2: Antibacterial activity of the acetonitrile extract of *Protoreaster linckii*

	Inhibition Zone (mm)				
	Concentrations of the extract µg/ml				
Pathogens	250	500	1000	Standard	Control
<i>Staphylococcus Saprophyticus</i>	10.12±0.28	10.30±0.72	11.00±0.36	20.00±0.12	----
<i>Escherichia coli</i>	11.36±0.20	11.40±0.45	11.69±0.31	18.21±0.31	----
<i>Klebsiella pneumonia</i>	6.900±1.04	7.700±0.35	8.500±0.42	6.800±0.36	----
<i>Pseudomonas aeruginosa</i>	6.300±0.20	7.400±0.56	9.700±0.53	18.52±0.16	----
<i>Enterobacter cloacae</i>	----	2.100±0.40	2.600±0.81	5.100±0.19	----
<i>Enterococcus faecalis</i>	2.600±0.31	2.800±0.56	3.400±0.70	5.300±0.23	----
<i>Staphylococcus aureus</i>	----	1.200±0.40	1.400±0.47	6.400±0.35	----
<i>Klebsiella oxytoca</i>	2.300±0.20	2.600±0.21	3.100±1.10	6.700±0.18	----
<i>Mycoplasma genitalium</i>	8.900±0.12	9.500±0.72	9.800±0.70	10.10±0.18	----
<i>Proteus mirabilis</i>	4.000±0.10	4.300±1.06	4.700±0.76	6.500±0.35	----

Table 3: Antibacterial activity of the dichloromethane extract of *Protoreaster linckii*

	Inhibition Zone (mm)				
	Concentrations of the extract µg/ml				
Pathogens	250	500	1000	Standard	Control
<i>Staphylococcus Saprophyticus</i>	11.50±0.36	12.31±0.31	12.49±0.65	20.00±0.12	----
<i>Escherichia coli</i>	10.59±0.81	11.46±0.45	12.13±0.31	18.21±0.31	----
<i>Klebsiella pneumonia</i>	2.900±0.76	3.300±0.56	4.500±0.42	6.800±0.36	----
<i>Pseudomonas aeruginosa</i>	12.50±0.81	13.10±0.67	13.70±0.53	18.52±0.16	----
<i>Enterobacter cloacae</i>	----	1.600±0.40	1.800±0.31	5.100±0.19	----
<i>Enterococcus faecalis</i>	2.500±0.64	2.600±0.40	2.800±0.59	5.300±0.23	----
<i>Staphylococcus aureus</i>	----	0.700±0.35	0.800±0.15	6.400±0.35	----
<i>Klebsiella oxytoca</i>	1.200±0.12	1.500±0.40	1.900±0.36	6.700±0.18	----
<i>Mycoplasma genitalium</i>	8.500±0.53	8.900±0.50	9.300±0.70	10.10±0.18	----
<i>Proteus mirabilis</i>	4.100±0.36	4.600±0.50	5.100±0.10	6.500±0.35	----

Table 4: Antibacterial activity of the ethanol extract of *Protoreaster linckii*

	Inhibition Zone (mm)				
	Concentrations of the extract µg/ml				
Pathogens	250	500	1000	Standard	Control
<i>Staphylococcus Saprophyticus</i>	11.12±0.36	12.30±0.42	14.00±0.76	20.00±0.12	----
<i>Escherichia coli</i>	11.56±0.31	12.13±0.31	12.39±0.64	18.21±0.31	----
<i>Klebsiella pneumonia</i>	6.300±0.56	6.700±0.76	7.500±0.47	6.800±0.36	----
<i>Pseudomonas aeruginosa</i>	6.700±0.32	7.100±0.47	8.700±0.43	18.52±0.16	----
<i>Enterobacter cloacae</i>	----	2.500±0.42	3.100±0.11	5.100±0.19	----
<i>Enterococcus faecalis</i>	2.400±0.81	2.900±0.81	3.800±0.15	5.300±0.23	----
<i>Staphylococcus aureus</i>	----	0.900±0.02	1.100±0.31	6.400±0.35	----
<i>Klebsiella oxytoca</i>	2.500±0.42	2.800±0.42	3.200±0.59	6.700±0.18	----
<i>Mycoplasma genitalium</i>	8.500±0.47	8.900±0.36	9.300±0.53	10.10±0.18	----
<i>Proteus mirabilis</i>	4.200±0.42	4.600±0.34	5.100±0.10	6.500±0.35	----




Figure 1.Antibacterial activity of the methanolic extract of *Protoreaster linckii*




Figure 2. Antibacterial activity of the acetonitrile extract of *Protoreaster linckii*




Figure 3. Antibacterial activity of the dichloromethane extract of *Protoreaster linckii*




Figure 4. Antibacterial activity of the ethanol extract of *Protoreaster linckii*

DISCUSSION

Urinary tract infection (UTI) is the most potent bacterial infection characterized by the proliferation of bacteria in urinary tract [26] and it results in fever, urinary urgency, dysuria, urinary frequency, cloudy and malodorous urine [27]. It is prevalent among infants and children, pregnant and older women [28-30]. Higher incidence of UTI was reported in females than the males [31]. Gram positive and gram negative pathogens including *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Enterococcus faecalis* and *Staphylococcus saprophyticus* are the most common causative agents of urinary tract infection [32]. Numerous studies were conducted regarding the antibiotic resistance of urinary tract infectious pathogens [33-35], which highlights the need of identifying new classes of natural compounds for clinical use. The present study was carried out to assess the antimicrobial activity of different extracts of starfish *P. linckii* against ten human UTI pathogens. Some of the earlier studies have also reported similar antibacterial activity in the sea star *P. linckii* [36-37]. Previous reports have also revealed that the antibacterial potential of certain other invertebrates [38-40]. The previous studies on the anti-microbial properties of starfishes along with compound analysis stated that steroidal glycosides, saponins and saponin like steroid derivatives were responsible for antimicrobial activity [18, 41]. Antimicrobial peptides (AMPs) present in Echinoderms were responsible for their humoral immunity [42]. Hence the elucidation and fractionation of compounds responsible for antimicrobial activity of the *P. linckii* should be taken into account.

4. CONCLUSION

The aim of the current study was to screen the extracts derived from starfish *Protoreaster linckii* for their activity against selected bacterial pathogens that are responsible for urinary tract infection. All the four extracts inhibited the growth of tested gram positive and gram negative pathogens. Methanolic extracts were found to be highly potent against all the pathogens and the maximum zone

of inhibition was reported against *Staphylococcus saprophyticus* and the minimum zone of inhibition was observed in the median concentration of dichloromethane extract against *S. aureus*. However further studies has to be conducted using other extracts with different concentrations. Considering the abundance of starfish *P. linckii*, results of the present study could be used as a baseline data for bioprospecting of the species for pharmaceutical applications.

ACKNOWLEDGEMENT

The authors are thankful to the University Grants Commission (UGC), New Delhi for the financial support in the form of Minor Research Project [Ref: MRP-6926/16(SERO/UGC)]. Authors were also grateful to Dr. A.K. Khaja Nazeemudeen Sahib, Secretary and Correspondent, Dr. S. Ismail Mohideen, Principal and Dr. I. Joseph A. Jerald, Head, P.G. and Research Department of Zoology, Jamal Mohamed College (Autonomous), Tiruchirappalli for their constant support and guidance throughout the research work.

CONFLICT OF INTEREST

None

REFERENCES

1. Venkataraman K, Raghunathan C. Coastal and marine biodiversity of India. In Marine Faunal Diversity in India 2015 (pp. 303-348). Academic Press.
2. Carson M, Clarke S. Bioactive compounds from marine organisms: Potential for bone growth and healing. *Marine drugs*. 2018;16(9):340.
3. Suleria H, Osborne S, Masci P, Gobe G. Marine-based nutraceuticals: An innovative trend in the food and supplement industries. *Marine drugs*. 2015; 13 (10): 6336-51.
4. Martins A, Vieira H, Gaspar H, Santos S. Marketed marine natural products in the pharmaceutical and cosmeceutical industries: Tips for success. *Marine drugs*. 2014; 12 (2): 1066-101.
5. Peng J, Shen X, El Sayed KA, Dunbar DC, Perry TL, Wilkins SP, Hamann MT, Bobzin S, Huesing J, Camp R, Prinsen M. Marine natural products as prototype agrochemical agents. *Journal of agricultural and food chemistry*. 2003; 51 (8): 2246-52.
6. Casas SM, Comesaña P, Cao A, Villalba A. Comparison of antibacterial activity in the hemolymph of marine bivalves from Galicia (NW Spain). *Journal of invertebrate pathology*. 2011; 106 (2): 343-5.
7. Haug T, Kjuul AK, Stensvåg K, Sandsdalen E, Styrvold OB. Antibacterial activity in four marine crustacean decapods. *Fish & shellfish immunology*. 2002; 12 (5): 371-85.
8. Abraham TJ, Nagarajan J, Shanmugam SA. Antimicrobial substances of potential biomedical importance from holothurian species. 2002; 2:161–164.
9. Guérard F, Decourcelle N, Sabourin C, Floch-Laizet C, Le Grel L, Le Floc'H P, Gourlay F, Le Delezir R, Jaouen P, Bourseau P. Recent developments of marine ingredients for food and

- nutraceutical applications: a review. *Journal des sciences Halieutique et Aquatique*. 2010; 2: 21-7.
10. Karasudani I, Koyama T, Nakandakari S, Aniya Y. Purification of anticoagulant factor from the spine venom of the crown-of-thorns starfish, *Acanthaster planci*. *Toxicon*. 1996; 34 (8): 871-9.
 11. Iorizzi M, Bryan P, McClintock J, Minale L, Palagiano E, Maurelli S, Riccio R, Zollo F. Chemical and biological investigation of the polar constituents of the starfish *Luidia clathrata*, collected in the Gulf of Mexico. *Journal of natural products*. 1995; 58 (5): 653-71
 12. Chludil HD, Seldes AM, Maier MS. Antifungal Steroidal Glycosides from the Patagonian Starfish *Anasterias m inuta*: Structure– Activity Correlations. *Journal of natural products*. 2002;65(2):153-7.
 13. Thao N, Cuong N, Luyen B, Quang T, Hanh T, Kim S, Koh YS, Nam N, Van Kiem P, Van Minh C, Kim Y. Anti-inflammatory components of the starfish *Astropecten polyacanthus*. *Marine drugs*. 2013; 11 (8): 2917-26.
 14. Haug T, Kjuul AK, Styrvold OB, Sandsdalen E, Olsen ØM, Stensvåg K. Antibacterial activity in *Strongylocentrotus droebachiensis* (Echinoidea), *Cucumaria frondosa* (Holothuroidea), and *Asterias rubens* (Asteroidea). *Journal of Invertebrate Pathology*. 2002; 81 (2): 94-102.
 15. Wang W, Li F, Alam N, Liu Y, Hong J, Lee CK, Im KS, Jung JH. New Saponins from the Starfish *Certanardoa s emiregularis*. *Journal of natural products*. 2002; 65 (11): 1649-56.
 16. Ngoan BT, Hanh TT, Vien LT, Diep CN, Thao NP, Thao DT, Thanh NV, Cuong NX, Nam NH, Thung DC, Kiem PV. Asterosaponins and glycosylated polyhydroxysteroids from the starfish *Culcita novaeguineae* and their cytotoxic activities. *Journal of Asian natural products research*. 2015; 17 (10): 1010-7.
 17. McClintock JB, Mahon AR, Peters KJ, Amsler CD, Baker BJ. Chemical defences in embryos and juveniles of two common Antarctic sea stars and an isopod. *Antarctic Science*. 2003;15 (3): 339-44.
 18. Ivanchina NV, Kicha AA, Kalinovsky AI, Dmitrenok PS, Stonik VA, Riguera R, Jiménez C. Hemolytic polar steroidal constituents of the starfish *Aphelasterias japonica*. *Journal of natural products*. 2000; 63 (8): 1178-81.
 19. Baveja M, Sarkar A, Chakrabarty D. Hemotoxic and wound healing potential of coelomic fluid of sea-star *Astropecten indicus*. *The Journal of Basic and Applied Zoology*. 2018; 79 (1): 27.
 20. Sarma NS, Krishna M, Pasha SG. Marine algal natural products: Contributions from India in the global context. *Indian J. Chem. Sec. B*. 2006; 45B, 433–449.
 21. Kanagarajan U, Bragadeeswaran S, Venkateshvaran K. On some toxinological aspects of the starfish *Stellaster equestris* (Retzius, 1805). *Journal of Venomous Animals and Toxins including Tropical Diseases*. 2008; 14 (3): 435-49.
 22. Karuppaiyan M. Diversity of Echinoderms along the southeast coast of India (Doctoral

- dissertation, Ph. D., Thesis. Annamalai University). 2007.
23. Chelladurai G, Balakrishnan S, Jayanthi G, Kumar KA, Mohanraj J. Report on the occurrence of abnormal four-armed red-knobbed starfish protoreaster linckii (Echinodermata: Astroidea), Tuticorin coast, south-east coast of India. *Marine Biodiversity Records*. 2015; 8: 1-4.
 24. Reddy SM, Srinivasulu M, Satyanarayana N, Kondapi AK, Venkateswarlu Y. New potent cytotoxic lamellarin alkaloids from Indian ascidian *Didemnum obscurum*. *Tetrahedron*. 2005; 61 (39): 9242-7.
 25. Reinheimer JA, Demkow MR, Candiotti MC. Inhibition of coliform bacteria by lactic cultures. *Australian Journal of Dairy Technology*. 1990; 45(1): 5-9.
 26. Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic *Escherichia coli* (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. *Frontiers in microbiology*. 2017; 8: 1566.
 27. Leung AKC, Wong AHC, Leung AAM, Hon KL. Urinary Tract Infection in Children. *Recent Pat Inflamm Allergy Drug Discov*. 2018; 13:1-17.
 28. Robinson JL, Finlay JC, Lang ME, Bortolussi R, Canadian Paediatric Society, Community Paediatrics Committee, Infectious Diseases and Immunization Committee. Urinary tract infection in infants and children: Diagnosis and management. *Paediatrics & child health*. 2014; 19 (6): 315-9.
 29. Matuszkiewicz-Rowińska J, Małyszko J, Wieliczko M. Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. *Archives of medical science: AMS*. 2015; 11 (1): 67.
 30. Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. *Jama*. 2014;311(8):844-54.
 31. Al-Badr A, Al-Shaikh G. Recurrent urinary tract infections management in women: a review. *Sultan Qaboos University Medical Journal*. 2013;13 (3): 359.
 32. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nature reviews microbiology*. 2015; 13 (5): 269.
 33. Olson RP, Harrell LJ, Kaye KS. Antibiotic Resistance in Urinary Isolates of *Escherichia coli* from College Women with Urinary Tract Infections. *Antimicrobial Agents and Chemotherapy*. 2009; 53 (3) 1285-1286
 34. Dickstein Y, Geffen Y, Andreassen S, Leibovici L, Paul M. Predicting antibiotic resistance in urinary tract infection patients with prior urine cultures. *Antimicrobial agents and chemotherapy*. 2016; 60 (8): 4717-21.
 35. Waller TA, Pantin SA, Yenior AL, Pujalte GG. Urinary Tract Infection Antibiotic Resistance in the United States. *Primary Care: Clinics in Office Practice*. 2018; 45 (3): 455-66.

36. Mariya V, Ravindran VS. Anti-human pathogenic potential and compositional studies on the extract of Seastar, *Protoreaster lincki* (Blainville, 1830) collected from Tuticorin, Southeast Coast, India. *Indian Journal of Geo-marine Science*. 2015; 44 (6):147-154
37. Kumaran NS, Bragadeeswaran S. Thangaraj. 2011. Antimicrobial activities in star fishes *Protoreaster lincki* (Blainville, 1830) and *Pentaceraster regulus* (Muller & Troschel, 1842) against isolated human, fish pathogenic and biofilm microorganisms. *Journal of Applied Sciences Research*.; 7 (6): 818-25.
38. Mojica ER, Layson ER, Rodil MC, Deocarís CC. Marine invertebrates as source of potential antitumor and antibacterial agents. *DLSU*. 2003; 1:1-11.
39. Devi P, Wahidulla S, Kamat T, D'Souza L. Screening marine organisms for antimicrobial activity against clinical pathogens. *Ind. J. Geo-Mar. Sci*. 2011; 338-346.
40. Anbukkarasu S, Subramanian B, Elayaperumal N, Masilamani M. Antimicrobial properties of partially purified extract of starfish *Luidia maculate*. *International Journal of Natural Products Research*. 2014; 4(4): 100-104.
41. Jha R, Zi-Rong X. Biomedical compounds from marine organisms. *Marine drugs*. 2004; 2 (3): 123-46.
42. Arizza V, Schillaci D. Echinoderm antimicrobial peptides: the ancient arms of the deuterostome innate immune system. In *Lessons in Immunity 2016* (pp. 159-176). Academic Press.